<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39557730</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2191-219X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>EJNMMI research</Title><ISOAbbreviation>EJNMMI Res</ISOAbbreviation></Journal><ArticleTitle>Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.</ArticleTitle><Pagination><StartPage>110</StartPage><MedlinePgn>110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13550-024-01163-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Peptide receptor radionuclide therapy (PRRT) with [<sup>177</sup>Lu]Lu-DOTA-TATE has emerged as a promising treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Its treatment protocol is currently standardised for all patients, resulting in different patient outcomes. This study investigates the variability of tumours and organs-at-risk (kidneys and red marrow) dosimetric parameters across treatment cycles in patients with pancreatic and intestinal NETs. Data from 37 patients enrolled in a prospective phase II study (LuMEn) were analysed. Treatment consisted of four cycles of [<sup>177</sup>Lu]Lu-DOTA-TATE administered 8-12 weeks apart. Three-time-point SPECT/CT imaging was performed after each treatment cycle, and dosimetry of tumours and organs-at-risk (kidneys and red marrow) was conducted following the medical internal radiation dose formalism. Coefficients of variation (CoV) assessed the variability of absorbed doses, activity concentrations on day 1, and effective half-lives. Linear mixed effect models (SAS software) were used to investigate the evolution of the dosimetric parameters over cycles, discerning between different primary NET types and grades of tumours.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There is an important variability in absorbed doses and activity concentrations among patients, particularly in tumours (CoV: ~50%). Tumour absorbed doses and activity concentrations decreased over treatment cycles in pancreatic NETs, although at a limited rate (~-13%/cycle). An opposite trend was observed for the kidneys ( ~ + 8%/cycle). Effective half-lives remained relatively constant across cycles for both organs-at-risk and tumours. The primary NET type significantly influenced effective half-lives in tumours, shorter in pancreatic NETs than intestinal NETs (77 h vs. 107 h, p &lt; 0.0001). No significant effect of the grade was observed on either of the variables investigated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study revealed considerable variations in tumour absorbed doses among patients with NETs treated with a standardized protocol. These findings confirm the need for personalized dosimetry approaches in PRRT, considering patient and tumour characteristics.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EudraCT Number: 2012-003666-41.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">gov identifier: NCT01842165. Registered 25 April 2013, https://clinicaltrials.gov/ct2/show/NCT01842165 .</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Danieli</LastName><ForeName>Rachele</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8013-4938</Identifier><AffiliationInfo><Affiliation>Medical Physics Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiophysics and MRI Physics Laboratory (ULB836), Université Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mileva</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Gwennaëlle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Physics Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiophysics and MRI Physics Laboratory (ULB836), Université Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristanto</LastName><ForeName>Paulus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Data Center, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delbart</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderlinden</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Physics Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiophysics and MRI Physics Laboratory (ULB836), Université Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wimana</LastName><ForeName>Zéna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiopharmacy Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendlisz</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levillain</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Physics Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiophysics and MRI Physics Laboratory (ULB836), Université Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynaert</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Physics Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiophysics and MRI Physics Laboratory (ULB836), Université Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flamen</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karfis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2158-3981</Identifier><AffiliationInfo><Affiliation>Nuclear Medicine Department, ENETS Centre of Excellence, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium. ioannis.karfis@hubruxelles.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01842165</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>Belgian National Cancer Plan</GrantID><Agency>Belgian National Cancer Plan</Agency><Country /></Grant><Grant><GrantID>Association Jules Bordet</GrantID><Agency>Association Jules Bordet</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EJNMMI Res</MedlineTA><NlmUniqueID>101560946</NlmUniqueID><ISSNLinking>2191-219X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Absorbed dose</Keyword><Keyword MajorTopicYN="N">Dosimetry</Keyword><Keyword MajorTopicYN="N">GEP-NETs</Keyword><Keyword MajorTopicYN="N">Neuroendocrine tumours</Keyword><Keyword MajorTopicYN="N">[177Lu]Lu-DOTA-TATE</Keyword></KeywordList><CoiStatement><b>Declarations</b> <b>Ethics approval and consent to participate</b> All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Jules Bordet Institute Ethics Committee (CE2034). Written informed consent was obtained from all study participants. <b>Consent for publication</b> Not applicable. <b>Competing interests</b> The authors have no competing interests to declare that are relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39557730</ArticleId><ArticleId IdType="doi">10.1186/s13550-024-01163-w</ArticleId><ArticleId IdType="pii">10.1186/s13550-024-01163-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discovery. 2020;19:589–608. https://doi.org/10.1038/s41573-020-0073-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0073-9</ArticleId><ArticleId IdType="pubmed">32728208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. https://doi.org/10.1007/s00259-014-2893-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-014-2893-5</ArticleId><ArticleId IdType="pubmed">25273832</ArticleId></ArticleIdList></Reference><Reference><Citation>Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of <sup>177</sup>Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1607427</ArticleId><ArticleId IdType="pubmed">28076709</ArticleId><ArticleId IdType="pmc">5895095</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high–dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807–17. https://doi.org/10.1016/S0140-6736(24)00701-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00701-3</ArticleId><ArticleId IdType="pubmed">38851203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of <sup>177</sup>Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nucl Med. 2023. https://doi.org/10.2967/jnumed.123.265987 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.123.265987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Assenat E, et al. Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [<sup>177</sup>Lu]Lu-DOTATATE: one step closer to personalized medicine. J Nucl Med. 2024. https://doi.org/10.2967/jnumed.123.267023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.123.267023</ArticleId><ArticleId IdType="pubmed">38637144</ArticleId><ArticleId IdType="pmc">11149595</ArticleId></ArticleIdList></Reference><Reference><Citation>Warfvinge CF, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, et al. Relationship between absorbed dose and response in neuroendocrine tumors treated with [<sup>177</sup>Lu]Lu-DOTATATE. J Nucl Med. 2024. https://doi.org/10.2967/jnumed.123.266991 . jnumed.123.266991.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.123.266991</ArticleId><ArticleId IdType="pubmed">38724277</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccauro M, Cuomo M, Bauckneht M, Bagnalasta M, Mazzaglia S, Scalorbi F, et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [<sup>177</sup>Lu]Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-024-06863-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-024-06863-y</ArticleId><ArticleId IdType="pubmed">39331131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandstrom M, Freedman N, Fross-Baron K, Kahn T, Sundin A. Kidney dosimetry in 777 patients during <sup>177</sup>Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Phys. 2020;7:73. https://doi.org/10.1186/s40658-020-00339-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40658-020-00339-2</ArticleId><ArticleId IdType="pubmed">33296054</ArticleId><ArticleId IdType="pmc">7726073</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth D, Gustafsson J, Warfvinge CF, Sundlov A, Akesson A, Tennvall J, et al. Dosimetric quantities in neuroendocrine tumors over treatment cycles with <sup>177</sup>Lu-DOTATATE. J Nucl Med. 2022;63:399–405. https://doi.org/10.2967/jnumed.121.262069 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262069</ArticleId><ArticleId IdType="pubmed">34272319</ArticleId><ArticleId IdType="pmc">8978188</ArticleId></ArticleIdList></Reference><Reference><Citation>Garske-Roman U, Sandstrom M, Fross Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of <sup>177</sup>Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970–88. https://doi.org/10.1007/s00259-018-3945-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-3945-z</ArticleId><ArticleId IdType="pubmed">29497803</ArticleId><ArticleId IdType="pmc">5915504</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, et al. Personalized <sup>177</sup>Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728–42. https://doi.org/10.1007/s00259-018-4209-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4209-7</ArticleId><ArticleId IdType="pubmed">30506283</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundlov A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based <sup>177</sup>Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49:3830–40. https://doi.org/10.1007/s00259-022-05786-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05786-w</ArticleId><ArticleId IdType="pubmed">35451612</ArticleId><ArticleId IdType="pmc">9399027</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn U, Ilan E, Sandstrom M, Lubberink M, Garske-Roman U, Sundin A. Peptide receptor radionuclide therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13050962 .</Citation></Reference><Reference><Citation>Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, et al. A dosimetry procedure for organs-at-risk in <sup>177</sup>Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med. 2018;56:41–9. https://doi.org/10.1016/j.ejmp.2018.11.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmp.2018.11.001</ArticleId><ArticleId IdType="pubmed">30527088</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Flamen P, Vandenberghe S. Accuracy and precision assessment for activity quantification in individualized dosimetry of <sup>177</sup>Lu-DOTATATE therapy. EJNMMI Phys. 2017;4:7. https://doi.org/10.1186/s40658-017-0174-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40658-017-0174-7</ArticleId><ArticleId IdType="pubmed">28127694</ArticleId><ArticleId IdType="pmc">5267757</ArticleId></ArticleIdList></Reference><Reference><Citation>Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937315</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiras A, Domenech-Massons JM, Cadarso C. Regression models: calculating the confidence interval of effects in the presence of interactions. Stat Med. 1998;17:2099–105. https://doi.org/10.1002/(sici)1097-0258(19980930)17:183C;2099::aid-sim9053E;3.0.co;2-6 .</Citation></Reference><Reference><Citation>Ardenfors O, Nilsson JN, Thor D, Hindorf C. Simplified dosimetry for kidneys and tumors in <sup>177</sup>Lu-labeled peptide receptor radionuclide therapy. EJNMMI Phys. 2022;9:44. https://doi.org/10.1186/s40658-022-00473-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40658-022-00473-z</ArticleId><ArticleId IdType="pubmed">35723797</ArticleId><ArticleId IdType="pmc">9209556</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavo Lena M, Partelli S, Castelli P, Andreasi V, Smart CE, Pisa E, et al. Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT). Endocr Pathol. 2020;31:119–31. https://doi.org/10.1007/s12022-020-09623-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12022-020-09623-4</ArticleId><ArticleId IdType="pubmed">32361926</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertelli M, Dotto A, Di Dato C, Malandrino P, Modica R, Versari A, et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord. 2021;22:563–79. https://doi.org/10.1007/s11154-020-09581-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-020-09581-6</ArticleId><ArticleId IdType="pubmed">32978685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirozzi Palmese V, D’Ambrosio L, Di Gennaro F, Maisto C, de Marino R, Morisco A, et al. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [<sup>177</sup>Lu]Lu-DOTATATE to favor its use in clinical practice. Eur J Nucl Med Mol Imaging. 2023;50:1753–64. https://doi.org/10.1007/s00259-023-06112-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-023-06112-8</ArticleId><ArticleId IdType="pubmed">36688980</ArticleId><ArticleId IdType="pmc">10119237</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipour R, Jackson P, Bressel M, Hogg A, Callahan J, Hicks RJ, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with <sup>177</sup>Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging. 2023;50:2997–3010. https://doi.org/10.1007/s00259-023-06257-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-023-06257-6</ArticleId><ArticleId IdType="pubmed">37184682</ArticleId><ArticleId IdType="pmc">10382388</ArticleId></ArticleIdList></Reference><Reference><Citation>Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following <sup>177</sup>Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Phys. 2018;5:33. https://doi.org/10.1186/s40658-018-0232-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40658-018-0232-9</ArticleId><ArticleId IdType="pubmed">30569328</ArticleId><ArticleId IdType="pmc">6300448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundlov A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, et al. Feasibility of simplifying renal dosimetry in <sup>177</sup>Lu peptide receptor radionuclide therapy. EJNMMI Phys. 2018;5:12. https://doi.org/10.1186/s40658-018-0210-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40658-018-0210-2</ArticleId><ArticleId IdType="pubmed">29974391</ArticleId><ArticleId IdType="pmc">6031553</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized <sup>177</sup>Lu-octreotate PRRT. EJNMMI Phys. 2018;5:25. https://doi.org/10.1186/s40658-018-0224-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40658-018-0224-9</ArticleId><ArticleId IdType="pubmed">30318563</ArticleId><ArticleId IdType="pmc">6186532</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, et al. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol. 2021;527:111226. https://doi.org/10.1016/j.mce.2021.111226 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2021.111226</ArticleId><ArticleId IdType="pubmed">33675866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, et al. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr Relat Cancer. 2014;21:691–704. https://doi.org/10.1530/ERC-14-0086 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-14-0086</ArticleId><ArticleId IdType="pubmed">25012983</ArticleId></ArticleIdList></Reference><Reference><Citation>Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res. 1999;59:3652–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10446977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansi R, Plas P, Vauquelin G, Fani M. Distinct in vitro binding profile of the somatostatin receptor subtype 2 antagonist [<sup>177</sup>Lu]Lu-OPS201 compared to the agonist [<sup>177</sup>Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel). 2021;14. https://doi.org/10.3390/ph14121265 .</Citation></Reference><Reference><Citation>Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PP. Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J. 1998;336:291–8. https://doi.org/10.1042/bj3360291 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3360291</ArticleId><ArticleId IdType="pubmed">9820803</ArticleId><ArticleId IdType="pmc">1219870</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006;155:849–57. https://doi.org/10.1530/eje.1.02307 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje.1.02307</ArticleId><ArticleId IdType="pubmed">17132755</ArticleId></ArticleIdList></Reference><Reference><Citation>Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of <sup>68</sup>Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353–9. https://doi.org/10.2967/jnumed.109.066662 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.066662</ArticleId><ArticleId IdType="pubmed">20150249</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli R, Milano A, Gallo S, Veronese I, Lascialfari A, Indovina L, et al. Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects. J Pers Med. 2022;12. https://doi.org/10.3390/jpm12020205 .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>